NNovo Nordisk Read More Novo Nordisk’s Dual Narrative: Promising Hemophilia Data and Steady Buybacks vs. a Glitch in the Obe2026-07-12 Novo Nordisk ended the week at €43.32, notching a 1.29% gain in Friday’s session. The move capped a…